It shows why clinical outcomes matter more than biological theories or promising biomarkers. person: Novo Nordisk / Reuters Exact publication date: 31 July 2026 Ziltivekimab reduced inflammatory narkers but did not significantly reduce heart attacks, strokes or cardiovascular deaths, illustrating why promising biological nechanisms do not always translate into improved patient outcomes. More serious infections were also reported in the treatment group.
Grab The link : https://www.reuters.com/legal/litigation/novo-nordisks-inflammation-drug-fails-reduce-cardiovascular-risk-trial-2026-07-31/